AR025135A1 - Una composicion farmaceutica, el uso de un derivado de cistina no peptidico, y nuevos derivados de cistina no peptidicos - Google Patents

Una composicion farmaceutica, el uso de un derivado de cistina no peptidico, y nuevos derivados de cistina no peptidicos

Info

Publication number
AR025135A1
AR025135A1 ARP990105639A ARP990105639A AR025135A1 AR 025135 A1 AR025135 A1 AR 025135A1 AR P990105639 A ARP990105639 A AR P990105639A AR P990105639 A ARP990105639 A AR P990105639A AR 025135 A1 AR025135 A1 AR 025135A1
Authority
AR
Argentina
Prior art keywords
peptidic
cystine
carbocyclic ring
aromatic
benzyloxycarbonyl
Prior art date
Application number
ARP990105639A
Other languages
English (en)
Original Assignee
Roche Olivier
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Roche Olivier filed Critical Roche Olivier
Publication of AR025135A1 publication Critical patent/AR025135A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/50—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton
    • C07C323/51—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C323/60—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton with the carbon atom of at least one of the carboxyl groups bound to nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/14—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/14—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D295/145—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
    • C07D295/15—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2603/00—Systems containing at least three condensed rings
    • C07C2603/02—Ortho- or ortho- and peri-condensed systems
    • C07C2603/04—Ortho- or ortho- and peri-condensed systems containing three rings
    • C07C2603/06—Ortho- or ortho- and peri-condensed systems containing three rings containing at least one ring with less than six ring members
    • C07C2603/10—Ortho- or ortho- and peri-condensed systems containing three rings containing at least one ring with less than six ring members containing five-membered rings
    • C07C2603/12—Ortho- or ortho- and peri-condensed systems containing three rings containing at least one ring with less than six ring members containing five-membered rings only one five-membered ring
    • C07C2603/18—Fluorenes; Hydrogenated fluorenes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Communicable Diseases (AREA)
  • Immunology (AREA)
  • Psychiatry (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Composiciones farmacéuticas que contienen derivados de cistina no peptídicos, de la formula general (1): en la cual R1 y R3 pueden ser iguales o diferentesy se seleccionan entre hidrogeno, un anillo heterocíclico o carbocíclico aromático o no aromático, o un grupo alquilo saturado o insaturado, lineal oramificado C1-15, que puede interrumpirse mediante un heteroátomo y que puede sustituirse a través de un anillo heterocíclico o carbocíclico aromático ono aromático. R2 y R4 pueden ser iguales o diferentes y se seleccionan entre hidrogeno, un grupo alquilo saturado o insaturado, lineal o mramificado, de 1 a 15átomos de carbono, que puede interrumpirse mediante un heteroátomo y que puede sustituirse a través de un anillo heterocíclico o carbocíclico aromático o noaromático, y A es un enlace de valencia o un grupo -CO-, SO2-, -NHCO-, NHCS- u -O-CO-, sus sales farmacologicamente aceptables y las formas opticamente activasde los mismos y los portadores farmacéuticamente aceptables, para el tratamiento de las enfermedades seleccionadas entre sí: el crecimiento tumoral y lametástasis, las enfermedades inflamatorias, como la osteoartritirs y artritis reumatoide, osteoporosis, esclerosis multiple, periodontitis, restenosis,enfermedades causadas por bacterias, tales como la meningitis, el envejecimiento de la piel inducido por el sol y el mal de Alzheimer, y nuevos compuestos dela formula general (1) en la cual R1, R2, R3 R4 y A tienen los valores dados anteriormente pero con la condicion de que si R2 y R4 son bencilo, R1-A y R3-A nopueden ser formilo, alquilcarbonilo C1-10, benzoilo, toluensulfonilo o benciloxicarbonilo, y si R1-A y R3-A son benciloxicarbonilo, R2 y R4 no pueden serpiridilmetilo, feniletilo, 4-hidroxifeniletilo, 4-clorofenilmetil, fenilpropilo o indoliletilo, sus sales farmacologicameante aceptables y las formasopticamente activas de los mismos.
ARP990105639A 1998-11-06 1999-11-08 Una composicion farmaceutica, el uso de un derivado de cistina no peptidico, y nuevos derivados de cistina no peptidicos AR025135A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP98121073 1998-11-06

Publications (1)

Publication Number Publication Date
AR025135A1 true AR025135A1 (es) 2002-11-13

Family

ID=8232930

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP990105639A AR025135A1 (es) 1998-11-06 1999-11-08 Una composicion farmaceutica, el uso de un derivado de cistina no peptidico, y nuevos derivados de cistina no peptidicos

Country Status (11)

Country Link
EP (1) EP1143960A2 (es)
JP (1) JP2002529404A (es)
KR (1) KR20010100983A (es)
CN (1) CN1346272A (es)
AR (1) AR025135A1 (es)
AU (1) AU1379600A (es)
BR (1) BR9915127A (es)
CA (1) CA2348946A1 (es)
TR (1) TR200101222T2 (es)
WO (1) WO2000027378A2 (es)
ZA (1) ZA200103605B (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6703031B1 (en) * 1998-10-09 2004-03-09 Ajinomoto Co., Inc. Cysteine derivatives
JP2002226457A (ja) * 2001-02-02 2002-08-14 Ajinomoto Co Inc 新規シスチン誘導体及び炎症因子活性化抑制剤
US7723328B2 (en) 2005-04-15 2010-05-25 The University Of North Carolina At Chapel Hill Methods of facilitating cell survival using neurotrophin mimetics
WO2011060262A1 (en) 2009-11-12 2011-05-19 Pharmatrophix, Inc. Crystalline forms of neurotrophin mimetic compounds and their salts
US10273219B2 (en) 2009-11-12 2019-04-30 Pharmatrophix, Inc. Crystalline forms of neurotrophin mimetic compounds and their salts
JP6838743B2 (ja) * 2015-06-08 2021-03-03 公立大学法人大阪 非ペプチド性ｇａｐｄｈ凝集阻害剤

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1478002A (en) * 1975-02-12 1977-06-29 Ecnpk Biolog I Mediko Biolog P Pharmaceutical composition having anti-tumour activity

Also Published As

Publication number Publication date
KR20010100983A (ko) 2001-11-14
JP2002529404A (ja) 2002-09-10
EP1143960A2 (en) 2001-10-17
AU1379600A (en) 2000-05-29
BR9915127A (pt) 2001-07-31
CA2348946A1 (en) 2000-05-18
CN1346272A (zh) 2002-04-24
TR200101222T2 (tr) 2001-12-21
WO2000027378A2 (en) 2000-05-18
ZA200103605B (en) 2001-12-11
WO2000027378A3 (en) 2001-09-20

Similar Documents

Publication Publication Date Title
AR016523A1 (es) Compuestos de indol como agentes anti-inflamatorios/analgesicos, composiciones farmaceuticas que los contienen y procedimiento de tratamiento
EE200100487A (et) Uudsed ühendid ja kompositsioonid proteaasiinhibiitoritena
PE20010130A1 (es) Derivados de 3(5)-amino-pirazol y procedimiento para su preparacion
GT200000005A (es) Derivados biciclicos sustituidos utiles como agentes contra el cancer.
AR021949A1 (es) UNA COMPOSICIONES ToPICA ,SU USO, Y, UN MÉTODO COSMÉTICO QUE LA UTILIZA.
PE20000339A1 (es) Biciclo [2.2.1] heptanos y compuestos relacionados
PT1075258E (pt) Analogos gordos novos para o tratamento da obesidade
AR048039A1 (es) Profarmacos de piperazina y agentes antivirales de piperidina sustituidos
ES2175350T3 (es) Compuestos triciclicos que tienen afinidad de union a receptores de melatonina, su produccion y uso.
CO4770945A1 (es) Composiciones orales antiplaca que contienen fenol alquila- tado antibacterial
ATE103812T1 (de) Zusammensetzung zur behandlung von ischaemischen stoerungen in organen.
ES2179353T3 (es) Antagonistas muscarinicos.
AR001931A1 (es) Compuesto de 7-acilamino-3-iminometil (sustituido)cefalosporinas un proceso para su producción intermediarios en su producción una composición farmacéutica que contiene tales compuestos su utilizacióncomo compuestos farmacéuticos y un método para tratar enfermedades microbianas mediante administración de tales compuestos
PE29798A1 (es) Acetidinas
AR025135A1 (es) Una composicion farmaceutica, el uso de un derivado de cistina no peptidico, y nuevos derivados de cistina no peptidicos
DK1063886T3 (da) Desinficerende middel
ES2143181T3 (es) Derivados biciclicos de isotiourea utiles en terapia.
AR012323A1 (es) Uso de compuestos de esteresaminas alcoxiladas o de formas cuaternizadas o protonizadas o de mezclas de los mismos en formulaciones establessuavizantes, detergentes, de limpieza o para la higiene personal y procedimiento para preparar composiciones de aplicacion en el uso mencionado
AR023369A1 (es) Secretagogos de la hormona del crecimiento
ATE337023T1 (de) Kontaktlinsenpflegemittel für harte und weiche kontaktlinsen
ES2058264T3 (es) Sulfonildecahidro-8h-isoquino(2,1-g)(1,6)naftiridinas, isomeros opticos de las mismas y compuestos afines.
DE60007289T2 (de) Verwendung von manzaminen als entzündungshemmende mittel
MX9307309A (es) Derivados de pirrolo, su preparacion y su aplicacion en terapeutica.
MX9303966A (es) Derivados de benzotiazepina y benzoxazepina.
AR008107A1 (es) Un compuesto de la familia de las aril 2,4-dioxo oxazolidinas, su utilizacion, procedimiento para su preparacion, composiciones cosmeticas yfarmaceuticas que lo contienen y un procedimiento de tratamiento cosmetico